RenovoRx, Inc. (RNXT) Stock Score, Valuation & Financial Research

RenovoRx, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RNXT

RenovoRx, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.13. These figures are a research snapshot, not a buy or sell recommendation.

What RenovoRx, Inc. does

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

RenovoRx is a clinical-stage biopharmaceutical company that develops novel precision oncology therapies. The company generates its business model through the development of its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which is designed to deliver therapeutic agents directly to solid tumors, and it seeks to commercialize this platform through clinical adoption and regulatory approval of its medical device, RenovoCath.

Products and services

  • The company's primary product is RenovoCath, a dual-balloon infusion catheter used for the targeted delivery of therapeutic agents to solid tumors via the TAMP therapy platform.

Brands and product families

  • RenovoCath — Proprietary dual-balloon infusion catheter used for targeted drug delivery. Source

Annual revenue by business

  • Other Operating Segment: USD 1,123,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Hospitals and medical centers; Physicians and clinical investigators.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its medical devices and clinical trial supplies; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary TAMP therapy platform technology Source
  • Growing clinical adoption and sales pipeline Source

Business risks and research considerations

  • History of operating losses and uncertainty of future profitability Source
  • Dependence on clinical trial success and regulatory approvals Source

Sources: Company research source · Other Operating Segment

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RNXT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.13
Market capitalization:
51.18M (currency not supplied)
Revenue:
USD 1.98M
Net income:
USD -12.29M
Free cash flow:
USD -10.98M
Cash:
USD 9.48M
Total debt:
USD 259K
EPS:
USD -0.32

What stands out

  • Reported year-over-year revenue growth is +76.0%.
  • Free cash flow is USD -10.98M, negative for the stored period.
  • The balance sheet shows USD 9.48M of cash versus USD 259K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -555.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -621.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 9.22M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RNXT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can RNXT sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can RNXT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RNXT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RNXT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RNXT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research RNXT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.